Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 204-208 , August 2010

Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy

  • Neil K. Taunk

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • ,
  • Sharad Goyal

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • Corresponding Author InformationCorresponding author at: Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08903, USA.
    • ,
  • Meena S. Moran

      Affiliations

    • Department of Therapeutic Radiology, Yale University School of Medicine, USA
    • ,
  • Qifeng Yang

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • Department of Breast Surgery, Qilu Hospital/Shandong University, People’s Republic of China
    • ,
  • Rahul Parikh

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA
    • ,
  • Bruce G. Haffty

      Affiliations

    • Department of Radiation Oncology, The Cancer Institute of New Jersey, NJ, USA

Received 8 September 2009 ,Revised 23 February 2010 ,Accepted 7 March 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Solin LJ, Fourquet A, Vicini FA, Taylor M, Haffty B, Strom EA, et al. Salvage treatment for local or local–regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer. 2005;41:1715–1723
  3. Smith IE, Arnedos M. The evolution of adjuvant endocrine therapy: developments since St. Gallen 2005. Breast. 2007;16:4–9
  4. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;11:4–12
  5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  7. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005;65:10123–10127
  8. Hartog H, Wesseling J, Boezen HM, Van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 2007;43:1895–1904
  9. Ullrich A, Gray A, Tam AW. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5:2503–2512
  10. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, et al. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem. 1988;263:11486–11492
  11. Renato Baserga FPKR. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–877
  12. Kaleko M, Rutter WJ, Miller D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990;10:464–473
  13. Yanochko G, Eckhart W. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 2006;8:R18
  14. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol. 2004;35:1537–1542
  15. Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer. 2001;85:2017–2021
  16. Hartog H, Wesseling J, Boezen HM, Van der Graaf WTA. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 2007;43:1895–1904
  17. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi J-C, Alexieva-Figusch J, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989;49:7002–7009
  18. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 1990;50:6931–6935
  19. Yu H, Levesque MA, Khosravi MJ. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer. 1996;74:1242–1247
  20. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–5657
  21. Haffty BG, Fischer D, Fischer JJ. Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1990;19:859–865
  22. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys. 2006;66:1320–1327
  23. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–877
  24. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Phys. 1997;109:565–571
  25. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57:3079–3083
  26. Railo MJ, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994;30A:307–311
  27. Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O, et al. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci. 2006;97:597–604
  28. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47
  29. Lee OH, Bae SK, Bae MH, Lee YM, Moon EJ, Cha HJ, et al. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer. 2000;82:385–391
  30. Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res. 1998;58:3243–3247

☆ This abstract was presented as an oral presentation at the 2008 Translational Advances in Radiation Oncology and Cancer Imaging Symposium in Arlington, Virginia on October 17–18, 2008 by N.K.T., who also received an ASTRO travel grant for this work. The Breast Cancer Research Foundation provided support to B.G.H. for this research.

PII: S0167-8140(10)00161-1

doi: 10.1016/j.radonc.2010.03.009

Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 204-208 , August 2010

Article Tools

* Image Usage & Resolution